BCL2 and acute myeloid leukemia: Venetoclax is a potent, selective inhibitor of BCL2, approved by the EMA and the AEMPS: (1) in combination with azacytidine or decitabine, for the treatment of newly diagnosed AML in adults who have comorbidities that preclude the use of intensive approaches and (2) for treatment of chronic lymphocytic leukemia (CLL) in combination with obinutuzumab or rituximab, or as monotherapy [42].